References
- Freedberg IM, Eisen AZ, Wolff K et al.Dermatology in General Medicine. McGraw-Hill, 44 (1999).
- Bonifati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermatol.38, 241–251 (1999).
- Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol. Clin.22, 449–459 (2004).
- Ettehadi P, Greaves WM, Wallach D, Aderka D, Camp RDR. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol.96, 146–151 (1994).
- Bonifati C, Carducci M, Cordial Fei P et al. Correlated increases of tumor necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease activity. Clin. Exp. Dermatol.19, 383–387 (1994).
- Mussi A, Bonifati C, Carducci M et al. Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents11, 115–118 (1997).
- Partsch G, Steiner G, Leeb BF, Dunky F, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol.2, 518–523 (1997).
- Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet356, 385–390 (2000).
- Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum.50, 2264–2272 (2004).
- Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol.42, 829–830 (2000).
- Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet357, 1842–1847 (2001).
- Gottleib AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol.139, 1627–1632 (2003).
- Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
- Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
- Enbrel, package insert. Amgen, CA, USA (2004).
- Sacher C, Rubbert A, König C, Scharffetter-Kochanek K, Kreig T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept. J. Am. Acad. Dermatol.46, 113–115 (2002).
- Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor α antagonist etanercept. Cutis74, 245–247 (2004).
- Lin M, Hsu C, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch. Dermatol.141, 680–682 (2005).
- Henter JI, Karlen J, Calming U, Bernstrand, Andersson U, Fadeel B. Successful treatment of Langerhans’-cell histiocytosis with etanercept. N. Engl. J. Med.345, 1577–1578 (2001).
- Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor α-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum.46, 1965–1968 (2002).
- Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum.48, 2645–2651 (2003).
- Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome by TNF-α blockade. Immunobiology206, 496–501 (2002).
- Cortis E, De Benedetti F, Insalaco A et al. Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. J. Pediatr.145, 851–855 (2004).
- Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Arch. Dermatol.140, 919–921 (2004).
- Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch. Dermatol.141, 13–15 (2005).
- Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br. J. Dermatol.144, 597–600 (2001).
- Robinson ND, Guitart J. Recalcitrant, recurrent apthous stomatitis treated with etanercept. Arch. Dermatol.139, 1259–1262 (2003).
- McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J. Drugs Dermatol.3, 441–444 (2004).
- Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor α-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.Arthritis Rheum.46, 1408–1409 (2002).
- Sfikakis PP. Behçet’s disease: a new target for anti-tumor necrosis factor treatment. Ann. Rheum. Dis.61(Suppl. II), ii51–ii53 (2002).
- Melikoglu M, Fresko I, Mat C et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J. Rheumatol.32, 98–105 (2005).
- Stambe C, Wicks IP. TNF-α and response of treatment-resistant adult-onset Still’s disease to thalidomide. Lancet352, 544–545 (1998).
- Husni ME, Maier AL, Mease PJ et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum.46, 1171–1176 (2002).
- Fautrel B, Sibilia J, Mariette X, Combe B. Tumor necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann. Rheum. Dis.64, 262–266 (2005).
- Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J. Am. Acad. Dermatol.51, 200–204 (2004).
- Utz JP, Limper AH, Kalra S et al. Etanercept for the treatment of stage II and stage III progressive pulmonary sarcoidosis. Chest124, 177–185 (2003).
- Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol.30, 1864–1867 (2003).
- Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum.43, S392 (2000) (Abstract).
- Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am. J. Clin. Dermatol.5, 403–416 (2004).
- Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host-disease pathologies. Blood91, 4051–4055 (1998).
- Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complimentary treatment for chronic graft-versus-host disease. Transplantation73, 665–667 (2002).
- Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalized pustular psoriasis induced by cyclosporine a withdrawal responding to the tumor necrosis factor α inhibitor etanercept. Dermatology205, 213–216 (2002).
- Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis72, 396–398 (2003).
- Lebwohl M. New developments in the treatment of psoriasis. Arch. Dermatol.138, 686–688 (2002).
- Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
- Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. North Am.29, 185–202 (2003).
- Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis.3, 148–155 (2003).
- Hamilton CD. Infectious complications of treatment with biologic agents. Curr. Opin. Rheumatol.16, 393–398 (2004).
- Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum.46, 3151–3158 (2002).
- Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum.50, 1740–1751 (2004).
- Adams AE, Zwicker J, Curiel C et al. Aggressive cutaneous T-cell lymphomas after TNFα blockade. J. Am. Acad. Dermatol.51, 660–662 (2004).
- Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum.44, 2862–2869 (2001).
- Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med.138, 807–811 (2003).
- Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol.22, 56–61 (2003).
- Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr. Opin. Rheumatol.12, 49–52 (2000).
- Maini R, St Clair EW, Breedveld et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet354, 1932–1939 (1999).
- Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117, 761–769 (1999).
- Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet359, 579–580 (2002).
Website
- Enbrel patient information www.enbrel.com